Hypertension vaccine is expected to be available within five years

In the near future, some patients with hypertension may be able to effectively control their blood pressure simply by injecting vaccines. The therapeutic vaccine is the result of years of research and development by a Swiss pharmaceutical company. At present, the vaccine is still in a small-scale clinical trial. 48 hypertensive patients have completed an injection course, and the expected antihypertensive effect can last about 4 months. It is reported that the vaccine will be launched within five years, and relevant research results have been published in the famous British medical journal The Lancet.
The hypertension vaccine mainly acts on the angiotensin system. When injected into the body, the vaccine will "infect" patients, stimulate the immune system to generate angiotensin antibodies, inhibit angiotensin, and lower blood pressure.    
Vaccine researchers believe that compared with traditional oral antihypertensive drugs, hypertension vaccines have many advantages. First, the half-life of oral antihypertensive drugs is short, and the blood pressure in the morning cannot be controlled stably, which is the high incidence time of stroke and myocardial infarction; The hypertension vaccine has no such concern. Tests have confirmed that the vaccine can ensure that patients' blood pressure drops significantly in the early morning. Second, the vaccine only needs to be injected three times a year, avoiding the trouble of taking drugs at designated points every day, and the compliance is obviously better than oral medicine. Third, some oral hypertension drugs are also treated according to the principle of angiotensin, but many patients stop taking them because they feel that the effect of lowering blood pressure is not obvious. There are also patients with large adverse reactions after taking it. The adverse reaction of hypertension vaccine is small, with only some flu like symptoms, which is more acceptable to patients.    
"Hypertension vaccine provides a new perspective for hypertension research. In 2007, a pharmaceutical company in the UK also announced that it had developed a vaccine based on the principle of angiotensin and entered Phase 2 clinical practice." Professor Ke Yuannan, director of the Department of Internal Medicine and Cardiology of the China Japan Friendship Hospital of the Ministry of Health, said in an interview with the Life Times, "But this vaccine also has defects, can not solve all problems, and is not applicable to some patients." There are many kinds of pathogenesis of hypertension, and the high activity of renin and angiotensin is only one mechanism. The vaccine targeting this system may not have a good effect on hypertension caused by other mechanisms. Therefore, many patients do not benefit from it.    
Ke Yuannan pointed out that vaccines developed in both the UK and Switzerland are far from large-scale clinical trials. It is unknown when they will be approved for marketing. It may be six or seven years after they enter China.